These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 13668339)

  • 1. [Gout; clinical and therapeutic study].
    DE SEZE S; RYCKEWAERT A; LEVERNIEUX J; MARTEAU R
    Rev Rhum Mal Osteoartic; 1959; 26(2-3):81-98. PubMed ID: 13668339
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gout: clinical and therapeutic study].
    DE SEZE S; RYCKEWAERT A; LEVERNIEUX J; MARTEAU R
    Reumatismo; 1958; 10(Supp 2):23-32. PubMed ID: 13602237
    [No Abstract]   [Full Text] [Related]  

  • 3. [Gout and diabetes].
    Bradna P
    Vnitr Lek; 2006 May; 52(5):488-92. PubMed ID: 16771097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of the management of gout in primary care.
    Owens D; Whelan B; McCarthy G
    Ir Med J; 2008 May; 101(5):147-9. PubMed ID: 18624262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and therapeutic observations on 43 patients suffering from primary gout].
    FRANK M; WURZEL M; ATSMON A; DE VRIES A
    Harefuah; 1961 Feb; 60():71-5. PubMed ID: 13701364
    [No Abstract]   [Full Text] [Related]  

  • 6. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D; Sripradit S; Angthararak S
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support.
    Colvine K; Kerr AJ; McLachlan A; Gow P; Kumar S; Ly J; Wiltshire C; Robinson E; Dalbeth N
    N Z Med J; 2008 Nov; 121(1285):73-81. PubMed ID: 19079439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
    Schumacher HR; Becker MA; Lloyd E; MacDonald PA; Lademacher C
    Rheumatology (Oxford); 2009 Feb; 48(2):188-94. PubMed ID: 19141576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
    Dalbeth N; Merriman T
    Rheumatology (Oxford); 2009 Mar; 48(3):222-6. PubMed ID: 19109320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in the scientific and clinical understanding of gout.
    So A
    Arthritis Res Ther; 2008; 10(5):221. PubMed ID: 18947374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. We can make gout management more successful now.
    Becker MA; Chohan S
    Curr Opin Rheumatol; 2008 Mar; 20(2):167-72. PubMed ID: 18349746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
    Bruce SP
    Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials in crystal arthropathy.
    Joseph-Ridge N; Cazzetta S; MacDonald P
    Rheum Dis Clin North Am; 2006 May; 32(2):359-82, vii. PubMed ID: 16716884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic challenges in the management of gout in the elderly.
    Singh H; Torralba KD
    Geriatrics; 2008 Jul; 63(7):13-8, 20. PubMed ID: 18593209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is gout associated with reduced quality of life? A case-control study.
    Roddy E; Zhang W; Doherty M
    Rheumatology (Oxford); 2007 Sep; 46(9):1441-4. PubMed ID: 17586863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insufficient evidence for oral glucocorticoids as first-line therapy for acute gout].
    Jacobs JW; Bijlsma JW
    Ned Tijdschr Geneeskd; 2009; 153():A615. PubMed ID: 19785794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life and disability in patients with treatment-failure gout.
    Becker MA; Schumacher HR; Benjamin KL; Gorevic P; Greenwald M; Fessel J; Edwards L; Kawata AK; Frank L; Waltrip R; Maroli A; Huang B; ; Sundy JS
    J Rheumatol; 2009 May; 36(5):1041-8. PubMed ID: 19332629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in the management of gout].
    Zaninetti-Schaerer A; Guerne PA
    Rev Med Suisse; 2007 Mar; 3(103):734-7. PubMed ID: 17458151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.